“…BACKGROUND: Chemotherapy regimens containing a combination of anti-Her2 antibodies are effective but can be associated with cardiac toxicity. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…In this article, we discuss that HER3-targeted therapies may be effective in treating patients with HER3-expressing CRC and PDAC, and highlight the importance of applying HER3 expression as a predictive biomarker for patient response to HER3-targeted therapies. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…PURPOSE: HER2 overexpression has a central role in breast cancer carcinogenesis and is associated with poor prognosis if untreated. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…RESULTS: The inconsistent expression rates of ER, PR, HER2, and Ki-67 in primary and metastatic lesions were 47.69%, 51.54%, 28.10%, and 29.23%, respectively. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…PURPOSE: This study aimed to compare the clinical behavior, clinicopathological and sociodemographic characteristics of patients with early-stage triple-negative breast cancer (TNBC) who belong to the HER2-low and HER2-zero subgroups. PATIENTS AND METHODS: This study involved a thorough search in the internal database of a single Brazilian institution to identify women with TNBC who underwent neoadjuvant chemotherapy (NACT) followed by curative surgery within the period from January 2010 to December 2014. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: Human epidermal growth factor receptor 2 (HER2) positive breast cancer is an aggressive subtype, accounting for around 20% of all breast cancers. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Data about young women with metastatic HER2-positive cancer who desire a pregnancy are scarce. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Mechanism studies were conducted to investigate the underlying basis of circ0030018 function in glioma, unveiling that circ0030018 realized its functions partially through the miR‐1236/HER2 signaling in glioma. In conclusion, our study investigated the roles and mechanisms of the ISL on the circ0030018/miR‐1236/HER2 pathway in glioma tumorigenesis and progression. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Overall serum exposure (cycle 1) of T-DXd, total anti-HER2 antibody, and DXd were similar regardless of HER2 status. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…INTRODUCTION: This study described, in routine clinical practice in Japan, the patient characteristics, treatment patterns, and outcomes of female patients with HR + /HER2- metastatic breast cancer (MBC) who started abemaciclib treatment. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Here, we report an improved overall survival of a HER2-positive metastatic breast cancer patient using a bioinformatic-based personalized peptide immunization called BITAP (BioInformatic Tumor Address Peptides). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…We herein used a BioSolveIT suite to identify potent inhibitors of EGFR and HER3. The schematic process involves screening of databases for constructing compound library comprising of 903 synthetic compounds (602 for EGFR and 301 for HER3) followed by pharmacophore modeling. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…METHODS: In this study, we expressed the recombinant anti-HER2 humanized monoclonal antibody (rhHER2-mAb) in human embryonic kidney 293 (HEK293) cells through transient gene expression (TGE) technology by constructing a mammalian cell expression vector. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The anti-HER2 component, KN026, is a recombinant, humanized bispecific antibody that targets both extra-cellular domains II (pertuzumab binding site) and IV (trastuzumab binding site) of HER2. …”
Enlace del recurso
Enlace del recurso

Enlace del recurso
Enlace del recurso
Enlace del recurso

“…We aim to investigate predictive factors of LVI in pre-neoadjuvant chemotherapy (NAC) patients with estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 negative (HER2−) molecular subtypes of breast cancer. MATERIALS AND METHODS: One hundred and thirty-four patients treated with NAC were included in this study who were ER+/HER2−. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: Approximately one third of patients with HER2-positive (+) metastatic breast cancer (MBC) develop brain metastases (BrM). …”
Enlace del recurso
Enlace del recurso

“…One contributing factor towards the development of CNS-metastases in breast cancer is HER2-positivity. Between 25%-48% of patients with HER2-positive metastatic breast cancer develop CNS-metastases. …”
Enlace del recurso
Enlace del recurso

“…BACKGROUND: Small tyrosine kinase inhibitors (TKIs) show activity against breast cancer brain metastases (BCBM) of the human epidermal growth factor receptor 2 (HER2)‐positive subtype. This meta‐analysis aimed to objectively explore the efficacy and safety of TKIs. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…This study aimed at exploring the expression and clinical significance of aromatase P450, adhesion molecule CD24 and HER2/neu in endometrial cancer. The expression of aromatase P450, adhesion molecule CD24 and HER2/neu was detected by immunohistochemistry in 15 cases of endometrial hyperplasia group, 50 cases of endometrial adenocarcinoma and 3 cases of uterine papillary adenocarcinoma, with 15 cases of normal endometrium as control group. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso